X4 Pharmaceuticals, Inc.
XFOR
$3.58
$0.072.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.85M | 9.01M | 35.11M | 33.98M | 32.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.85M | 9.01M | 35.11M | 33.98M | 32.77M |
| Cost of Revenue | 2.93M | 1.64M | 5.76M | 5.70M | 5.57M |
| Gross Profit | 12.92M | 7.38M | 29.36M | 28.28M | 27.20M |
| SG&A Expenses | 31.00M | 32.02M | 40.12M | 47.88M | 55.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.02M | 102.02M | 117.30M | 127.98M | 138.66M |
| Operating Income | -83.17M | -93.01M | -82.18M | -94.00M | -105.89M |
| Income Before Tax | -90.17M | -99.72M | -79.16M | -94.80M | -101.63M |
| Income Tax Expenses | -28.00K | 7.00K | 41.00K | 299.00K | 344.00K |
| Earnings from Continuing Operations | -90.14 | -99.72 | -79.20 | -95.10 | -101.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.14M | -99.72M | -79.20M | -95.10M | -101.98M |
| EBIT | -83.17M | -93.01M | -82.18M | -94.00M | -105.89M |
| EBITDA | -81.50M | -91.99M | -80.91M | -92.67M | -104.52M |
| EPS Basic | -1.41 | -4.75 | -4.55 | -10.01 | -14.80 |
| Normalized Basic EPS | -0.81 | -2.90 | -2.77 | -6.15 | -9.22 |
| EPS Diluted | -1.41 | -4.75 | -4.55 | -10.01 | -14.80 |
| Normalized Diluted EPS | -0.81 | -2.90 | -2.77 | -6.15 | -9.22 |
| Average Basic Shares Outstanding | 407.35M | 288.42M | 168.97M | 64.29M | 27.71M |
| Average Diluted Shares Outstanding | 407.35M | 288.42M | 169.00M | 64.32M | 27.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |